Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system

Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system

Abstract Background Monitoring of anticoagulant activity of direct oral anticoagulants (DOACs) can be necessary in special situations. DOAC plasma levels have a high inter‐ and intraindividual variation and do not necessarily reflect the coagulation status of the patient. Thrombin generation (TG) is...

Bibliografske podrobnosti
Main Authors:	Christian Pfrepper, Michael Metze, Annelie Siegemund, Tristan Klöter, Thomas Siegemund, Sirak Petros
Format:	Article
Jezik:	English
Izdano:	Elsevier 2020-05-01
Serija:	Research and Practice in Thrombosis and Haemostasis
Teme:	anti‐Xa‐inhibitors correlation dabigatran DOAC plasma levels ST Genesia thrombin generation
Online dostop:	https://doi.org/10.1002/rth2.12340

Podobne knjige/članki

Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants
od: Michael Metze, et al.
Izdano: (2020-05-01)

Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: Assessment of analytical and between‐subject variation
od: Søren Risom Kristensen, et al.
Izdano: (2022-01-01)

Calibrated automated thrombogram II: removing barriers for thrombin generation measurements
od: P. L. A. Giesen, et al.
Izdano: (2021-08-01)

Factor Xa and thrombin induce endothelial progenitor cell activation. The effect of direct oral anticoagulants
od: Styliani Papadaki, et al.
Izdano: (2021-08-01)

The novel anticoagulants: entering a new era
od: Swiss Medical Weekly
Izdano: (2009-02-01)

Semi-automated thrombin dynamics applying the ST Genesia thrombin generation assay
od: Audrey Carlo, et al.
Izdano: (2022-07-01)

Direct oral anticoagulant blood level monitoring in daily practice
od: R. Bavalia, et al.
Izdano: (2021-05-01)

Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the Calibrated Automated Thrombogram
od: Tuukka A. Helin, et al.
Izdano: (2021-03-01)

Thrombocytopenia induced by dabigatran: two case reports
od: Hyun Goo Kang, et al.
Izdano: (2017-06-01)

Serial thrombin generation and exploration of alternative anticoagulants in critically ill COVID-19 patients: Observations from Maastricht Intensive Care COVID Cohort
od: Tom W. van de Berg, et al.
Izdano: (2022-10-01)

Thrombin-induced platelet aggregation −effect of dabigatran using automated platelet aggregometry−
od: Mie Shimizu, et al.
Izdano: (2020-04-01)

Practical issues in measuring the anticoagulant effect of direct oral anticoagulants
od: Dopsaj Violeta
Izdano: (2020-01-01)

Dabigatran Plasma Measurement to Guide the Management of Acute Bleeding and Thrombotic Complications
od: Maurizio Tala, et al.
Izdano: (2018-09-01)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
od: Jong-Min Kim, et al.
Izdano: (2022-01-01)

Direct oral anticoagulants in cirrhosis: Rationale and current evidenceKeypoints
od: Cindy Pereira Portela, et al.
Izdano: (2024-08-01)

Clinical characteristics of patients with direct oral anticoagulant (DOAC) levels outside expected ranges: A retrospective chart study
od: Dionne C.W. Braeken, et al.
Izdano: (2023-05-01)

Comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in dogs
od: Alex M. Lynch, et al.
Izdano: (2024-11-01)

Direct oral anticoagulants; a review for the non-specialist
od: Thilina Gunawardena
Izdano: (2021-11-01)

Direct oral anticoagulant: Review article
od: Abdulrahman Nasiri, et al.
Izdano: (2022-01-01)

The new way of Dabigatran reversal – Idarucizumab
od: Erwin Ciechański, et al.
Izdano: (2019-02-01)

The new way of Dabigatran reversal – Idarucizumab
od: Erwin Ciechański, et al.
Izdano: (2019-02-01)

Hospital consumption of direct oral anticoagulants in regions of the Russian Federation in 2017–2022
od: A. V. Matveev, et al.
Izdano: (2024-01-01)

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
od: Yin Lu, et al.
Izdano: (2022-01-01)

Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: Normal values and variability
od: Sara Calzavarini, et al.
Izdano: (2019-10-01)

Distinct pleiotropic effects of direct oral anticoagulants on cultured endothelial cells: a comprehensive review
od: Natalia Atzemian, et al.
Izdano: (2023-09-01)

Dabigatran etexilate - A novel oral anticoagulant for bleeding complications
od: Himabindu Reddy, et al.
Izdano: (2015-09-01)

Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale
od: Shaw Shaw, et al.
Izdano: (2023-07-01)

Is There an Alternative Oral Anticoagulation to Vitamin-K-Antagonists for Patients with Mechanical Aortic Valve Replacement? – A Literature Review
od: Stephen Gerfer, et al.
Izdano: (2024-05-01)

Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants
od: Emmanuel J. Favaloro, et al.
Izdano: (2022-02-01)

Thrombin and factor Xa link the coagulation system with liver fibrosis
od: Ameet Dhar, et al.
Izdano: (2018-05-01)

An update on applications and limitations of direct oral anticoagulants
od: Sharon Wei, et al.
Izdano: (2023-04-01)

Analytical performance of the endogenous thrombin potential–based activated protein C resistance assay on the automated ST Genesia system
od: Laure Morimont, et al.
Izdano: (2022-03-01)

Direct Thrombin Inhibitor Dabigatran Compromises Pulmonary Endothelial Integrity in a Murine Model of Breast Cancer Metastasis to the Lungs; the Role of Platelets and Inflammation-Associated Haemostasis
od: Marta Smeda, et al.
Izdano: (2022-02-01)

Dabigatran mitigates cisplatin-mediated nephrotoxicity through down regulation of thrombin pathway
od: Mohamed Gamal El-Din Ewees, et al.
Izdano: (2021-07-01)

Reference values for thrombin dynamics in platelet rich plasma
od: Qiuting Yan, et al.
Izdano: (2021-02-01)

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
od: Jana Úlehlová, et al.
Izdano: (2021-11-01)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
od: Maha Al-Ghafry, et al.
Izdano: (2022-10-01)

Dabigatran etexilate: a direct thrombin inhibitor
od: M. Dugnani
Izdano: (2013-05-01)

Safety of Dabigatran as an Anticoagulant: A Systematic Review and Meta-Analysis
od: Ya Zhou, et al.
Izdano: (2021-02-01)

Viscoelastometry for detecting oral anticoagulants
od: Philipp Groene, et al.
Izdano: (2021-03-01)